StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Adempas / Verquvo (sGC stimulator alliance with Bayer by Quarter

Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International reported growth YoY (%) (%)

QuarterlyAnnual

Merck Adempas / Verquvo (sGC stimulator alliance with Bayer: -1.0% in Q2 2026, down 90.0 pts from a year earlier.

Latest, Q2 2026
-1.0%
Period ended Jun 30, 2026
Change on a year earlier
-90.0 pts
89.0% in Q2 2025
History
14 quarters
Since Q1 2020
Sources
14
Documents cited below

Where the Q2 2026 figure comes from

“|| Alliance Revenue - Adempas/Verquvo (5) | 126 | 123 | 3 | 112 | 108 | 4 | 14 | 15 | -1”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-1.0%-90.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 202525.0%–Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202589.0%–Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 202512.0%+63.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 2024-27.0%–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2024Mar 31, 2024-51.0%–Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q2 2023Jun 30, 2023-119.0%–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q3 2022Sep 30, 2022-90.0%–Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2022Mar 31, 2022-82.0%-104.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 2021-42.0%–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q1 2021Mar 31, 202122.0%-111.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q3 2020Sep 30, 2020117.0%–Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020141.0%–Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020133.0%–Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗

Cite this data

StockData. (2026). Merck Adempas / Verquvo (sGC stimulator alliance with Bayer (%), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-adempas-verquvo-intl-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.